Blue Sail Medical acquires Swiss medtech company NVT AG

The finalization of this deal brings together NVT’s expertise in innovative Transcatheter Aortic Valve Implantation technology, and Biosensors’ solid track record in Interventional Cardiology.

“The closing of this transaction represents a new and exciting era for the company, and specifically the new Structural Heart business unit, as we seek to continue improve patients’ lives through pioneering medical technology. It broadens the company’s assets and will provide strategic growth opportunities, particularly in the transcatheter aortic valve replacement market. Together, we look forward to leveraging and further accelerating Biosensor’s drive to deliver the greatest possible patient outcomes.” commented Mr Brian Fan Yang, Blue Sail Executive Committee Member & CEO Biosensors International Group. 

Biosensors Intl. is a subsidiary of Blue Sail Medical, with 25 years experience in designing, manufacturing and marketing innovative medical devices, including devices for Percutaneous Coronary Intervention. The company has worldwide operations, and combines direct sales teams with a worldwide distribution network.

NVT’s ALLEGRA TAVI system is a self-expanding supra-annular transcatheter aortic valve, which presents unique design features and similar event rates compared to contemporary devices. The most recent data, presented during PCR London Valves 2019, shows positive outcomes for the ALLEGRA TAVI system in a Valve-in-Valve setting at 12 months in the VIVALL trial. On 29 April 2020, the device received CE approval for Valve-in-Valve indication. The TAVI market is growing at about 15% worldwide, Europe and the US being the main markets to date. In EMEA, the market is forecasted to reach nearly 85,000 procedures next year. China is also seen as a very important growth market over the next five years.